Author

C. I. Kaku

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 5 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:host-pathogen & immune response· 6 Approach:experimental assay· 5 Organism:human· 4 Assay:proteomics· 4 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

L. M. Walker· 6 shared D. R. Burton· 3 shared G. Song· 3 shared R. Andrabi· 3 shared C. G. Rappazzo· 2 shared D. Nemazee· 2 shared H. Liu· 2 shared I. A. Wilson· 2 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersImmunology

L. M. Walker

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Characteristics and functions of infection-enhancing antibodies to the N-terminal domain of SARS-CoV-2

R. I. Connor, M. I. Sakharkar, C. G. Rappazzo, C. I. Kaku, N. C. Curtis, S. Shin, W. F. Wieland-Alter, J. A. Weiner, M. E. Ackerman, L. M. Walker, J. Lee, P. F. Wright

This study identifies infection-enhancing antibodies targeting the N-terminal domain of SARS-CoV-2 spike protein, which persist in convalescent patients and may be counteracted by viral mutations.

bioRxiv · Sep 19, 2023Immunology

Evolution of antibody immunity following Omicron BA.1 breakthrough infection

C. I. Kaku, T. N. Starr, P. Zhou, H. L. Dugan, P. Khalife, G. Song, E. R. Champney, D. W. Mielcarz, J. C. Geoghegan, D. R. Burton, R. Andrabi, J. D. Bloom, L. M. Walker

This study tracks antibody responses six months after Omicron BA.1 breakthrough infection and finds reduced neutralizing antibodies and memory B cells, with public clones dominating and predicting new sublineages.

bioRxiv · Sep 21, 2022 · PreprintImmunology

Recall of pre-existing cross-reactive B cell memory following Omicron breakthrough infection

C. I. Kaku, A. J. Bergeron, C. Ahlm, J. Normark, M. Sakharkar, M. N. Forsell, L. M. Walker

BA.1 breakthrough infection activates pre-existing memory B cells with broad activity against SARS-CoV-2 variants.

bioRxiv · Apr 1, 2022 · PreprintImmunology

A broad and potent neutralization epitope in SARS-related coronaviruses

M. Yuan, X. Zhu, W.-t. He, P. Zhou, C. I. Kaku, T. Capozzola, C. Y. Zhu, X. Yu, H. Liu, W. Yu, Y. Hua, H. Tien, L. Peng, G. Song, C. Cottrell, , I. A. Wilson

The paper identifies a broadly neutralizing epitope in SARS-related coronaviruses that is effective against variants, including Omicron, and suggests its use for universal vaccine design.

bioRxiv · Mar 13, 2022 · PreprintMicrobiology

A recurring YYDRxG pattern in broadly neutralizing antibodies to a conserved site on SARS-CoV-2, variants of concern, and related viruses

H. Liu, C. I. Kaku, G. Song, M. Yuan, R. Andrabi, D. R. Burton, L. M. Walker, I. A. Wilson

The paper identifies a YYDRxG motif in antibodies that broadly neutralize SARS-CoV-2 variants and related viruses, suggesting a conserved epitope targeting strategy.

bioRxiv · Dec 15, 2021 · PreprintImmunology

An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19

C. G. Rappazzo, L. V. Tse, C. I. Kaku, D. Wrapp, M. Sakharkar, D. Huang, L. M. Deveau, T. J. Yockachonis, A. S. Herbert, M. B. Battles, C. M. O'Brien, M. E. Brown, J. C. Geoghegan, J. Belk, L. Peng, , L. M. Walker

This study engineers an antibody, ADG-2, that broadly neutralizes SARS-CoV and SARS-CoV-2 in mice, offering protection against respiratory disease and viral replication.

bioRxiv · Nov 17, 2020 · PreprintImmunology